Other (Income)/Deductions - Net - Schedule of Other (Income)/Deductions - Net (Detail) - USD ($) $ in Millions		3 Months Ended
		Apr. 03, 2022	Apr. 04, 2021
Other Income and Expenses [Abstract]
Interest income		$ (14)	$ 0
Interest expense		322	336
Net interest expense		308	336
Royalty-related income		(173)	(176)
Net (gains)/losses on asset disposals		(1)	(39)
Net (gains)/losses recognized during the period on equity securities	[1],[2]	699	(401)
Income from collaborations, out-licensing arrangements and sales of compound/product rights	[3]	(9)	(231)
Net periodic benefit costs/(credits) other than service costs		(283)	(266)
Certain legal matters, net		79	51
Consumer Healthcare JV equity method (income)/loss	[4]	(184)	(62)
Other, net		(88)	(216)
Other (income)/deductions––net		$ 350	$ (1,004)

[1] Reported in Other (income)/deductions––net. See Note 4.

[2] The losses in the first quarter of 2022 include, among other things, unrealized losses of $473 million related to our investment in BioNTech. The gains in the first quarter of 2021 included, among other things, unrealized gains of $409 million related to investments in Allogene Therapeutics, Inc. and BioNTech.

[3] The first quarter of 2021 included, among other things, $188 million of net collaboration income from BioNTech related to Comirnaty.

[4] See Note 2C